Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

298
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
298
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

309
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
309
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

628
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
628
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

319
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
319
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

274
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
274
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

264
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
264

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids.

Journal of neuroendocrinology·2026
Same author

The NET Score: An Interpretable AI-Assisted Prognostic Score for Mortality Risk in Lung Neuroendocrine Tumors.

Endocrine-related cancer·2026
Same author

Safety and Efficacy of Single-Stage Synchronous Bilateral VATS Talc Poudrage for Malignant Pleural Effusion.

Cancers·2026
Same author

Concordance of Actionable Driver Alterations Between Primary Lung Adenocarcinoma and Paired Thoracic Metastases: A Prospective Next-Generation Sequencing Study.

Cancers·2026
Same author

Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. <i>Cancers</i> 2026, <i>18</i>, 1037.

Cancers·2026
Same author

Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jan 13, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.4K

Recurrent Malignant Pericardial Effusion Management: The Pericardio-Peritoneal Window.

Antonio Mazzella1, Giovanni Caffarena1, Claudia Bardoni1

  • 1Division of Thoracic Surgery, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.

Journal of Clinical Medicine
|January 10, 2026
PubMed
Summary
This summary is machine-generated.

The pericardio-peritoneal window (PPW) is a safe and effective surgical option for managing malignant pericardial effusion (MPE) in patients with a good prognosis. For those with a less favorable outlook, pericardial drainage is recommended.

Keywords:
lung cancermalignant pericardial effusionpericardial effusionpericardial metastasespericardio-peritoneal window

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

521

Related Experiment Videos

Last Updated: Jan 13, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.4K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

521

Area of Science:

  • Oncology
  • Cardiothoracic Surgery
  • Palliative Care

Background:

  • Malignant pericardial effusion (MPE) is a rare but challenging complication of solid tumors.
  • Management of MPE often requires effective and safe therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and long-term outcomes of the pericardio-peritoneal window (PPW) as a definitive treatment for MPE.
  • To compare PPW with other management strategies for MPE.

Main Methods:

  • Retrospective and prospective analysis of 44 patients undergoing PPW between 2010 and 2023.
  • Data collected included surgical procedures, complications, mortality, and relapse rates.
  • Associated procedures like videothoracoscopy and percutaneous drainage were noted.

Main Results:

  • The 30-day mortality rate was 9%.
  • The success rate for PPW, defined as absence of relapse requiring further intervention, was 95.5%.
  • Recurrence of pericardial effusion occurred in 8 patients, with only 2 requiring further intervention.

Conclusions:

  • Pericardio-peritoneal window (PPW) is a safe and effective definitive treatment for MPE in patients with a favorable short-term prognosis.
  • Percutaneous pericardial drainage is a more appropriate therapy for patients with a less favorable prognosis.